Health X Platform Ltd Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 1
Margin
Category 1
Fundraise
No
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 1- Target total revenue by 2030: Rs. 6,600 crores (combined SastaSundar and RetailerShakti).
- SastaSundar platform expected revenue by 2030: Rs. 2,000 crores (60% CAGR from current year).
- RetailerShakti expected revenue by 2030: Rs. 4,500 crores (36% CAGR from current year).
- Current year (FY '24-'25) projected revenue: Rs. 1,191 crores total (approx. Rs. 200 crores from SastaSundar, Rs. 1,000 crores from RetailerShakti).
- RetailerShakti growth: 100% year-over-year from last year, aiming for CAGR of 36% over next five years.
- SastaSundar aims to expand SKU portfolio (currently 37,000 SKUs) and launch private label "Aadhaar Pharma" with ~500 SKUs.
- EBITDA profitability expected: RetailerShakti by FY '25-'26 and improving to 4%-5% EBITDA margin by 2030.
- Plans to double RetailerShakti revenue from Rs. 489 crores (FY '23-'24) to Rs. 1,000 crores (FY '24-'25).
See what Health X Platform Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- There is no mention of any planned new fundraising through debt or equity in the disclosed transcript.
- Banwari Lal Mittal emphasized that the company aims to build the business over the next three years using existing cash reserves without leveraging.
- Current cash and near-cash assets stand substantial (around Rs. 675 crores), which management believes is sufficient to support their growth plans.
- The expected growth targets (CAGR of 41% leading to Rs. 6,600 crores turnover by 2030) are planned to be achieved without raising additional capital.
- The management's focus is on capital efficiency and sustainable profit growth rather than seeking new external capital.
- The Japanese marquee investors are supportive and have consented to current investments, but there's no indication of fresh fundraising planned.
See what Health X Platform Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- SastaSundar plans to invest around Rs. 145 crores in fresh capital expenditure mainly focused on building the SastaSundar platform and RetailerShakti businesses.
- This investment will come from existing capital raised (including Rs. 96 crores from the Flipkart deal) and treasury income.
- The Rs. 145 crores will be primarily expenses booked in the Profit & Loss account for technology build-up (self-developed products), salaries for engineers, and marketing/advertisement.
- There are no plans for manufacturing; instead, SastaSundar will partner with existing manufacturers.
- Expansion plans include opening one new ALC (warehouse) for RetailerShakti in the next 2-3 years (from current three ALCs to a total of four).
- Strategic alliances are being explored for expanding the Genu Path Labs (pathology business), integrating it with the quick health platform.
- The company aims to remain capital-efficient, avoiding excessive leverage, to grow profitably over the next three years.
Track Health X Platform Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- RetailerShakti is expected to grow at a CAGR of 36% over the next five years, with profitability anticipated around FY 2025-26 when it reaches approximately Rs. 2,000 crores revenue.
- SastaSundar platform aims for a 60% growth CAGR, targeting Rs. 2,000 crores in revenue by 2030.
- Overall, the combined business aims for Rs. 6,600 crores turnover by 2030, reflecting a blended revenue CAGR of 41% (60% for SastaSundar, 36% for RetailerShakti).
- The blended gross margin is targeted to increase to about 11% by 2030, with EBITDA margins for the total business expected between 4%-5% by 2030.
- RetailerShakti is expected to achieve positive EBITDA by FY 2025-26 and progressively improve to 1-3% EBITDA margins from FY 2026-27 onwards.
- The focused investment of around Rs. 145 crores is expected to be profitable, with PAT profitability at the platform level projected after one year of these investments.
Order book
How does Health X Platform Ltd rank vs peers in Healthcare Services?
Pro featureHow does Health X Platform Ltd rank in Healthcare Services?
Compare Health X Platform Ltd against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Health X Platform Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
- Shalby Ltd (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…
- Nephrocare Health Services Ltd (Q1 FY27)
International operations contribute around 45% of revenue, reflecting their growing importance in overall growth. Key concall takeaways from Nephrocare Health…